Insulet
PODD | NASDAQ
$145.38
-$7.10 (-4.66%)
At close: Nov 16, 2026, 4:00 PM ET
$145.29
-$0.09 (-0.06%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Insulet Company Profile
Company profile explainedCompany Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Ashley A. McEvoy | Chief Executive Officer, President & Director |
| Amit Guliani | Senior Vice President & Chief Technology Officer |
| Eric Benjamin | Executive Vice President & Chief Operating Officer |
| Flavia H. Pease | Executive Vice President & Chief Financial Officer |
| Angela Geryak Wiczek | Senior Director of Corporate Communications |
| Chuck Medovich | Senior VP and Chief Quality, Regulatory & Compliance Officer |
| Clare Trachtman | Vice President of Investor Relations |
| John Wodick Kapples | Senior Vice President & General Counsel |
| Philip Hildale | Senior Vice President of Sales & Customer Care |
| Prem Singh | Senior Vice President of Global Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 05, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Sep 21, 2026 | 8-K | Current Report |
| Sep 16, 2026 | 8-K | Current Report |
| Sep 10, 2026 | 8-K | Current Report |
| Aug 24, 2026 | 4 | Filing |
| Aug 06, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 05, 2026 | 10-Q | Quarterly Report |
Insulet
| Country | United States |
| IPO Date | May 15, 2007 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 5,400 |
| CEO | Ashley McEvoy |
Contact Details
100 Nagog Park Acton,
Massachusetts 01720 United States
Stock Details
| Ticker Symbol | PODD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001145197 |
| CUSIP Number | 45784P101 |
| ISIN Number | US45784P1012 |
| SIC Code | 3841 |
Recent News
- 4 days ago / zacks.comWhy Insulet (PODD) is a Top Growth Stock for the Long-Term
- 4 days ago / zacks.comInsulet (PODD) Just Overtook the 20-Day Moving Average
- 5 days ago / seekingalpha.comInsulet: Rivals Are Building Patch Pumps, But Insulet Already Owns The Pharmacy Counter
- 6 days ago / zacks.comIs Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think "Yes"
- 8 days ago / businesswire.comFor World Diabetes Day, Insulet Launches “Give Yourself the Freedom to” Campaign, Encouraging People with Diabetes to Prioritize Their Well-Being
- 12 days ago / marketbeat.comWhat Insulet (PODD) Said on Its Q3 Earnings Call
- 13 days ago / seekingalpha.comInsulet Corporation (PODD) Q3 2026 Earnings Call Transcript
- 13 days ago / zacks.comInsulet (PODD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- 13 days ago / zacks.comInsulet (PODD) Q3 Earnings and Revenues Surpass Estimates
- 14 days ago / businesswire.comInsulet to Participate in the 2026 Jefferies Global Healthcare Conference in London
Add to Watchlist
Select watchlists to add or remove PODD